Paired Ends: Charles Dadswell | GenomeWeb

Paired Ends: Charles Dadswell

Premium

Illumina has named Charles Dadswell senior vice president and general counsel, replacing Christian Cabou, who has retired. Dadswell will be responsible for all legal and intellectual property matters and will also serve as secretary to Illumina's board of directors. He joins Illumina from BioMérieux, where he served as vice president and general counsel for North and Latin America and corporate director of global intellectual property.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.